Experimental HCV Drugs
Experimental HCV Drugs
EASL International Liver Congress Starts this Week in Amsterdam
- Details
- Category: HBV Treatment
- Published on Monday, 22 April 2013 00:00
- Written by Liz Highleyman
The 
48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) kicks off this Wednesday, April 24, at the Amsterdam RAI congress center. HIVandHepatitis.com will be on site to provide breaking news and analysis starting later this week.
Gilead Submits New Hepatitis C Drug Sofosbuvir for FDA Approval
- Details
- Category: HCV Treatment
- Published on Wednesday, 10 April 2013 00:00
- Written by Gilead Sciences
Gilead Sciences this week submitted a New Drug Application (NDA) requesting approval of its investigational HCV polymerase inhibitor sofosbuvir (formerly GS-7977) as part of interferon-free therapy with ribavirin for people with HCV genotypes 2/3 or a shorter interferon-based regimen for those with harder-to-treat genotypes.
CROI 2013: New Treatments for Hepatitis C and HIV/HCV Coinfection
- Details
- Category: HCV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Liz Highleyman
New treatments for hepatitis C were a key focus at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) this month in Atlanta. Researchers described several next-generation direct-acting antiviral agents for both HCV monoinfected and HV/HCV coinfected people, as well as some interferon-free regimens.
CROI 2013: Advances in Hepatitis C Treatment 2013 [VIDEO]
- Details
- Category: HCV Treatment
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
The advent of direct-acting antiviral agents targeting hepatitis C virus (HCV) have brought about a new era of treatment, but many questions remain about how these new medications will be used in real-world clinical practice.
[Produced in collaboration with IFARA]
In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Marks from Weill Cornell Medical Center spoke with Liz Highleyman of HIVandHepatitis.com about implications of new therapies for hepatitis C patients and providers.
CROI 2013: Sofosbuvir + Ribavirin Works Well for Inner-City Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 March 2013 00:00
- Written by Liz Highleyman
A simple 24-week, all-oral regimen of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 chronic hepatitis C, many of whom had factors predictive of poor response, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
More Articles...
- CROI 2013: AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients
- Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo
- CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected
- CROI 2013: Simeprevir + Sofosbuvir Demonstrates Good Early Cure Rate With or Without Ribavirin
Web Design and Development by